Skip to main content
TipRanks
Go Ultimate75% OFF

Aprogen, Inc (007460) Stock Price & Analysis

007460 Stock Chart & Stats

₩1,709.00-₩11.00(-0.64%)
At close: 3:30 PM GMT+9
₩1.75K₩2K₩2.25K₩2.5KAug 24Sep 7Sep 21Oct 6Oct 19Nov 2Nov 16
Day’s Range
KRW 1,674.00 - KRW 1,759.00
52-Week Range
KRW 1,615.00 - KRW 14,070.00
Previous Close
KRW 1,720.00
Volume
N/A
Average Volume (3M)
101.51K
Market Cap
KRW 8.36B
Enterprise Value
KRW 546.73B
Total Cash (Recent Filing)
KRW 43.16B
Total Debt (Recent Filing)
KRW 181.45B
Price to Earnings (P/E)
―
Beta
0.28
Next Earnings
Mar 29, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Recent revenue growth indicates that Aprogen is expanding its commercial or development-related activity despite weak profitability. If the company can sustain this top-line momentum, it may provide a broader base over which operating efficiencies and future biologic product contributions can develop.

Biologic Medicines Focus

A focus on biologics, biosimilars, and antibody-based therapeutics places Aprogen in markets where specialized development and production capabilities are important. This business orientation can support durable relevance as healthcare demand increasingly includes biologic treatment options.

Recombinant Protein And Cell-Culture Capabilities

Recombinant protein and cell-culture technologies, combined with related production capabilities, give Aprogen an established technical foundation for its biologics pipeline. These capabilities can support repeated development and manufacturing efforts across multiple therapeutic programs over time.

Bears Say

Persistent Deep Losses

Persistent, deep losses show that revenue growth is not currently translating into a viable earnings base. Continued negative operating and net results may restrict internal reinvestment, reduce financial resilience, and require the company to improve economics before growth can create shareholder value.

Sustained Cash Burn

Consistently negative operating and free cash flow means Aprogen is not funding operations and investment from internally generated cash. The worsening TTM free-cash-flow deficit increases dependence on external funding and can constrain the pace or sustainability of future development activity.

Rising Leverage And Weaker Capital Cushion

The sharp increase in debt-to-equity and decline in equity materially weaken Aprogen's capital cushion. Higher leverage can limit financial flexibility, increase pressure to fund obligations while losses continue, and make it harder to absorb setbacks in development or production.

007460 FAQ

What was Aprogen, Inc’s price range in the past 12 months?
Aprogen, Inc lowest stock price was ₩1615.00 and its highest was ₩14070.00 in the past 12 months.
What is Aprogen, Inc’s market cap?
Aprogen, Inc’s market cap is ₩8.36B.
When is Aprogen, Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aprogen, Inc’s earnings last quarter?
Aprogen, Inc released its earnings results on Nov 16, 2026. The company reported -₩1,649.084 earnings per share for the quarter.
Is Aprogen, Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Aprogen, Inc pay dividends?
Aprogen, Inc does not currently pay dividends.
What is Aprogen, Inc’s EPS estimate?
Aprogen, Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aprogen, Inc have?
Aprogen, Inc has 25,650,015 shares outstanding.
What happened to Aprogen, Inc’s price movement after its last earnings report?
Aprogen, Inc reported an EPS of -₩1,649.084 in its last earnings report. Following the earnings report the stock price went down -3.615%.
Which hedge fund is a major shareholder of Aprogen, Inc?
Currently, no hedge funds are holding shares in KR:007460
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology